

Estrella Immunopharma I/I EB103

T

EMERYVILLE, CALIFORNIA, UNITED STATES, August 6, 2024
/EINPresswire.com/ -- Estrella Immunopharma, Inc. ESLESLAW “Estrella” I/I STARLIGHT-1 EB103 / R/ROB NHL T CAR-T B “Mehrdad Abedi” NHL HIV CNS NHL CRS EB103 ARTEMIS®



T B NHL “STARLIGHT-1 I/I EB103” Estrella Immunopharma “ARTEMIS T CAR-T EB103 B NHL CD19” Naseem Esteghamat EB103 I/I EB103 T B NHL ≥18 RP2D clinicaltrials.gov NCT NCT06343311 EB103 EB103 T Estrella “CD19 ARTEMIS® T” Eureka Therapeutics, Inc. “Eureka” ARTEMIS® Eureka Estrella CAR-T ARTEMIS® T EB103 T EB103

